Polyp Biopsy Market Report 2025

The polyp biopsy market size has grown strongly in recent years. It will grow from $1.27 billion in 2024 to $1.39 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period is attributed to increasing awareness of colorectal cancer screening, rising prevalence of gastrointestinal disorders, expansion of hospital and diagnostic infrastructure, government-supported screening programs, and technological advancements in biopsy forceps.

The polyp biopsy market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period is driven by rising demand for minimally invasive procedures, increased adoption of disposable biopsy devices, healthcare investments in early cancer detection, expanding insurance coverage for diagnostic procedures, and an aging global population boosting screening rates. Key trends in the forecast period include the integration of artificial intelligence in biopsy analysis, development of robotic-assisted biopsy procedures, growing use of disposable and single-use devices, preference for outpatient and ambulatory care centers, and a shift toward personalized medicine and precision diagnostics.

The growing prevalence of colorectal cancer is expected to contribute significantly to the expansion of the polyp biopsy market. Colorectal cancer is a malignant condition that develops in the colon or rectum, originating from abnormal and uncontrolled growth of epithelial cells lining the large intestine. This form of cancer is known for its ability to invade nearby tissues and spread to other parts of the body. The increase in colorectal cancer cases is largely attributed to common dietary habits that are high in processed foods and low in fiber. These habits can cause chronic inflammation, disrupt gut microbiota, and encourage the formation of precancerous growths that may eventually become cancerous. Polyp biopsy plays a critical role in addressing this trend by facilitating early detection and histological examination of abnormal lesions, thereby enabling timely treatment and reducing the risk of disease progression. For example, in 2025, the American Cancer Society, a nonprofit organization based in the United States, estimated that there would be 107,320 new cases of colon cancer and 46,950 new cases of rectal cancer in the country, with approximately 52,900 deaths expected as a result. As such, the rising incidence of colorectal cancer is fueling demand for polyp biopsy procedures.

Key companies in the polyp biopsy market are investing in advanced technologies such as artificial intelligence-assisted detection systems to improve the identification of colorectal polyps and enable earlier recognition of potentially cancerous lesions. An artificial intelligence-assisted detection system is a medical tool that evaluates imaging data in real time to detect abnormalities and generate visual alerts for healthcare providers, assisting them in making informed clinical decisions without delivering therapeutic treatments. For example, in September 2024, Odin Medical Ltd., a medical technology firm based in the United States and affiliated with Olympus Corporation, introduced CADDIE, a cloud-based artificial intelligence endoscopy platform. The CADDIE system analyzes colonoscopy footage in real time, identifying areas that may contain colorectal polyps and allowing clinicians to make better decisions during the examination. Clinical evaluations showed that the system improves the rate of adenoma detection without increasing the time or risk involved in the procedure, demonstrating its effectiveness in supporting early diagnosis and improving patient care.

In October 2024, Caldera Medical, a medical device manufacturer based in the United States, acquired UVision360, Inc. for an undisclosed amount. Through this acquisition, Caldera Medical gains access to UVision360's advanced hysteroscopy technology, including the LUMINELLE Bx system, which enhances the company’s offerings in minimally invasive diagnostic and treatment options for uterine conditions such as polyps, fibroids, and other intrauterine abnormalities. UVision360 is a company based in the United States that develops hysteroscopy and cystoscopy systems, including the LUMINELLE platform.

Major players in the polyp biopsy market are Johnson & Johnson (Ethicon), Medtronic plc, Medline Industries LP, FUJIFILM Holdings Corporation, Stryker Corporation, Becton Dickinson and Company (BD), Boston Scientific Corporation, B. Braun Melsungen AG, Olympus Corporation, STERIS plc, Hologic Inc., Cooper Surgical Inc., KARL STORZ SE & Co. KG, Cook Medical, ConMed Corporation, Ambu A/S, Richard Wolf GmbH, INRAD, Acheron Instruments (Pvt) Ltd., Innovia Medical.

North America was the largest region in the polyp biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in polyp biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the polyp biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

A polyp biopsy is a medical procedure in which a healthcare professional removes a small tissue sample from an abnormal growth, or polyp, on the lining of an organ or body cavity. The sample is examined under a microscope to assess cellular characteristics, detect disease, and support accurate diagnosis and treatment planning. This procedure helps determine the nature of polyps, distinguish between benign and malignant conditions, and provide critical information for guiding clinical management or surveillance strategies.

The primary types of polyp biopsy are colonoscopy, colposcopy-directed biopsy, esophagogastroduodenoscopy, and laryngoscopy. Colonoscopy with polyp biopsy involves inserting a flexible camera (colonoscope) into the colon to visualize the intestinal lining and remove tissue samples for diagnostic evaluation. Techniques include endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and conventional biopsy. These procedures are distributed through online channels, retail pharmacies, and other outlets, and are applied in areas such as colorectal cancer and gastrointestinal disorders. End-users include hospitals, diagnostic laboratories, and specialty clinics.

The polyp biopsy market research report is one of a series of new reports that provides polyp biopsy market statistics, including polyp biopsy industry global market size, regional shares, competitors with a polyp biopsy market share, detailed polyp biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the polyp biopsy industry. This polyp biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The polyp biopsy market consists of revenues earned by entities by providing services such as endoscopic ultrasound (EUS), capsule endoscopy, double-balloon enteroscopy, single-balloon enteroscopy, push enteroscopy, transnasal endoscopy, and transanal endoscopic microsurgery (TEM). The market value includes the value of related goods sold by the service provider or included within the service offering. The polyp biopsy market also includes sales of hot biopsy forceps, cold biopsy forceps, endoscopic snares, polypectomy snares, cytology brushes, biopsy needles (fine-needle aspiration needles, core biopsy needles), and endoscopic ultrasound needles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.